We conducted the subanalysis described herein to clarify whether the effects of canagliflozin on NT-proBNP, BMI, and other laboratory parameters differ among patients with vs. without obesity. This evidence concerns the gene NPPB and obesity due to melanocortin 4 receptor deficiency.